Denali Therapeutics Inc. (DNLI), a Healthcare Biotechnology organization, saw its stock trade 23.28 common shares, a higher demand against to its 10-day trading volume of 1.57M.
Denali Therapeutics Inc. (DNLI) stock is quoted at $23.28, up -1.70 cents or -6.81% on the day. Based on this we can see some traders are either waiting on the sidelines to get involved or perhaps some are taking profits.
Total Revenue for Denali Therapeutics Inc. (DNLI) is $147.68M, Gross Profit is $-12.12M and the EBITDA is $-70.49M.
Denali Therapeutics Inc. (DNLI) Technical Figures:
The average 10-day trading volume of Denali Therapeutics Inc. (DNLI) is 1.57M compared to 536.41k over the last 3 months which indicates a pullback in trading activity. At the time of writing, Denali Therapeutics Inc. (DNLI) has a 50-day moving average of $20.38 and a 200-day moving average of $18.20. These moving averages are popular technical details that investors use to analyze price trends of Denali Therapeutics Inc. (DNLI).
Approximately 10.87% of the shares of the company are sold short from investors betting the stock might trade lower. The beta value on Denali Therapeutics Inc. (DNLI) stock is 2.11, indicating its 13.17% to 9.07% more volatile than the overall global market.
Technically, DNLI’s short term support levels are around $22.16, $19.95 and $18.85 on the downside. DNLIs short term resistance levels are $26.45 and $23.36 on the upside.
Based on technical analysis, DNLI has short term rating of Neutral (0.22), Intermediate rating of Neutral (0.19) and the long-term rating of Bullish (0.47) giving it an overall rating of Bullish (0.29).
DNLI is trading 63.48% off its 52 week low at $14.24 and -23.45% off its 52 week high of $30.41. Performance wise, DNLI stock has recently shown investors -6.51% a higher demand in a week, 34.80% a higher demand in a month and 50.29% a higher demand in the past quarter.
On the flip side, Denali Therapeutics Inc. (DNLI) has shown a return of 33.64% since the beginning of the year.
Denali Therapeutics Inc. (DNLI) Key Research:
Denali Therapeutics Inc. (DNLI) is a mid-cap company with a market cap value of $2.236B. DNLI insiders hold roughly 8.80% of the shares.
On Sep-13-19 Nomura Initiated DNLI as Buy, On Sep-26-19 Wedbush Initiated DNLI as Neutral at $19 and on Jan-27-20 Goldman Upgrade DNLI as Neutral → Buy at $20 → $37.
There are currently 87.58M shares in the float and 89.41M shares outstanding. There are 10.87% shares short in DNLIs float.
The industry rank for Denali Therapeutics Inc. (DNLI) is 73 out of 255 ranking it at the Top 29% .
Denali Therapeutics Inc. (DNLI) Fundamental Research:
DNLI last 2 years revenues have increased from $129,160 to $147,682 showing an uptrend.
Wall Street expects Denali Therapeutics Inc. (DNLI) to report an EPS next Qtr profit of -0.56 and a profit of -18.80% next year.
The growth rate on DNLI this year is -417.95 compared to an industry 8.10. However, DNLIs next year’s growth rate is -18.32 compared to an industry 8.30.
The book value per share (mrq) is 4.57 and cash per share (mrq) is 5.36. Giving them a price/book (mrq) of 5.10 compared to an industry of 3.75.
DNLI fundamental ratios shows an EPS growth vs. previous year -2.02 and EPS growth vs. previous quarter -0.49.
About Denali Therapeutics Inc. (DNLI):
Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States.